ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Celanese has signed two agreements to promote the use of its ethylene vinyl acetate–based drug delivery technology, VitalDose. The chemical maker will work with Alessa Therapeutics to develop sustained–release oncology drugs using technology from both firms. Meanwhile, Celanese and Johns Hopkins University’s Department of Ophthamology will study sustained delivery of drugs for retinal disorders to the suprachoroidal space in the eye.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter